Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CERONASDAQ:CYTONASDAQ:GLTONYSE:MTNB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCEROCERo Therapeutics$0.46+2.6%$0.70$0.40▼$102.00$3.53M0.661.50 million shs1.97 million shsCYTOAltamira Therapeutics$0.30-25.9%$0.36$0.30▼$1.59$1.02M1.8268,109 shs753,013 shsGLTOGalecto$3.17+3.1%$2.81$2.01▼$16.07$4.19M1.28171,395 shs16,234 shsMTNBMatinas Biopharma$0.82$0.64$0.47▼$9.60$4.15M1.19196,858 shs40,066 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCEROCERo Therapeutics0.00%-16.57%-48.06%-69.29%-99.52%CYTOAltamira Therapeutics0.00%0.00%0.00%0.00%-80.39%GLTOGalecto0.00%+3.01%+4.01%-22.44%-79.54%MTNBMatinas Biopharma0.00%0.00%+33.11%+46.04%+337.26%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCEROCERo Therapeutics3.1238 of 5 stars3.24.00.00.02.40.80.0CYTOAltamira TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AGLTOGalecto3.4858 of 5 stars3.55.00.00.03.60.81.3MTNBMatinas BiopharmaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCEROCERo Therapeutics 2.33Hold$7.001,431.73% UpsideCYTOAltamira Therapeutics 0.00N/AN/AN/AGLTOGalecto 3.00Buy$10.00215.86% UpsideMTNBMatinas Biopharma 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownLatest CYTO, MTNB, CERO, and GLTO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/30/2025CEROCERo TherapeuticsD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/30/2025CEROCERo TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold5/19/2025CEROCERo TherapeuticsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$3.004/22/2025CEROCERo TherapeuticsD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/22/2025CEROCERo TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$11.00 ➝ $11.00(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCEROCERo TherapeuticsN/AN/AN/AN/A($259.05) per shareN/ACYTOAltamira Therapeutics$320K3.19N/AN/A$4.56 per share0.07GLTOGalectoN/AN/AN/AN/A$29.81 per shareN/AMTNBMatinas Biopharma$1.10M3.77N/AN/A$4.43 per share0.18Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCEROCERo Therapeutics-$2.54MN/A0.00∞N/AN/AN/A-108.43%N/ACYTOAltamira Therapeutics-$4.31MN/A0.00N/AN/AN/AN/AN/AN/AGLTOGalecto-$38.35M-$15.53N/AN/AN/AN/A-76.96%-66.59%8/11/2025 (Estimated)MTNBMatinas Biopharma-$22.94M-$3.86N/A∞N/AN/A-123.06%-94.28%N/ALatest CYTO, MTNB, CERO, and GLTO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025N/ACEROCERo TherapeuticsN/A-$1.59N/A-$1.59N/AN/A5/8/2025Q1 2025GLTOGalectoN/A-$1.92N/A-$1.92N/AN/A3/19/2025Q4 2024GLTOGalecto-$3.12-$5.22-$2.10-$5.22N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCEROCERo TherapeuticsN/AN/AN/AN/AN/ACYTOAltamira TherapeuticsN/AN/AN/AN/AN/AGLTOGalectoN/AN/AN/AN/AN/AMTNBMatinas BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCEROCERo TherapeuticsN/A0.390.39CYTOAltamira TherapeuticsN/A0.43N/AGLTOGalectoN/A8.688.68MTNBMatinas BiopharmaN/A5.535.53Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCEROCERo Therapeutics29.64%CYTOAltamira Therapeutics1.91%GLTOGalecto14.20%MTNBMatinas Biopharma11.77%Insider OwnershipCompanyInsider OwnershipCEROCERo Therapeutics12.72%CYTOAltamira Therapeutics13.03%GLTOGalecto10.80%MTNBMatinas Biopharma4.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCEROCERo Therapeutics87.72 million2.49 millionN/ACYTOAltamira Therapeutics203.40 million2.96 millionNot OptionableGLTOGalecto401.32 million1.16 millionOptionableMTNBMatinas Biopharma305.09 million4.60 millionN/ACYTO, MTNB, CERO, and GLTO HeadlinesRecent News About These CompaniesMatinas BioPharma amends bylaws, updates on officer agreementsMay 4, 2025 | investing.comMatinas BioPharma files to sell 16.9M shares of common stock for holdersApril 24, 2025 | markets.businessinsider.comMatinas BioPharma secures shareholder nods on key proposalsApril 6, 2025 | investing.comMatinas BioPharma announces board chairman’s departureMarch 16, 2025 | investing.comMatinas BioPharma appoints Murphy, Neugeboren to board of directorsMarch 11, 2025 | markets.businessinsider.comMatinas BioPharma Appoints Seasoned Biotech Leaders to Board of DirectorsMarch 11, 2025 | finance.yahoo.comMatinas BioPharma Announces Agreement for the Acquisition of Preferred Stock and Appointment of Dr. Robin L. Smith to the Board of DirectorsFebruary 13, 2025 | globenewswire.comMatinas BioPharma announces board member retirementFebruary 11, 2025 | msn.comMatinas BioPharma Appoints Evelyn D’An as Independent Director and Audit Committee ChairFebruary 9, 2025 | nasdaq.comMatinas BioPharma appoints Evelyn D’An to board of directorsFebruary 7, 2025 | markets.businessinsider.comMatinas BioPharma Appoints Evelyn D’An to Board of Directors as Audit Committee ChairFebruary 7, 2025 | finance.yahoo.comMatinas BioPharma Appoints Evelyn D'An to Board of Directors as Audit Committee ChairFebruary 7, 2025 | globenewswire.comMatinas BioPharma announces board member resignationJanuary 25, 2025 | msn.com111 Equity Group increases stake in Matinas BioPharmaJanuary 25, 2025 | markets.businessinsider.com111 Equity ups stake in Matinas Biopharma HoldingsJanuary 24, 2025 | msn.com111 Equity Group increases stake in Matinas Biopharma Holdings, Inc.January 24, 2025 | finance.yahoo.comWhat Factors Have Led to Matinas BioPharma Holdings Inc (MTNB) Stock Trading -96.74% Below Its 52-Week High?January 15, 2025 | bovnews.comMatinas BioPharma Receives NYSE Noncompliance NoticeJanuary 10, 2025 | globenewswire.comMatinas BioPharma Faces Uncertain Future After Halting MAT2203 DevelopmentNovember 16, 2024 | markets.businessinsider.comMatinas BioPharma downgraded to Neutral from Buy at Alliance Global PartnersNovember 2, 2024 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCYTO, MTNB, CERO, and GLTO Company DescriptionsCERo Therapeutics NASDAQ:CERO$0.46 +0.01 (+2.16%) As of 03:56 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.Altamira Therapeutics NASDAQ:CYTOAltamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the treatment of rheumatoid arthritis; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase II/III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It also offers Bentrio, a drug-free nasal spray for protection against airborne viruses and allergens. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. The company was founded in 2003 and is based in Hamilton, Bermuda.Galecto NASDAQ:GLTO$3.17 +0.10 (+3.13%) As of 03:50 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.Matinas Biopharma NYSE:MTNB$0.82 0.00 (0.00%) As of 03:56 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Buy The Dip in Okta, There’s Nothing Wrong With the Outlook Why SoundHound Could Be a Short Squeeze in the Making Why Schwab US Dividend Equity ETF Could Lead the Rotation Analysts Are Bullish on Marvell Stock Despite Amazon Deal Concern MarketBeat Week in Review – 05/26 - 05/30 Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell 5 Reasons Costco Stock Will Hit New Highs This Year Ackman Takes a Swing at Amazon — Should You? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
